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Comorbidities are associated with increased mortality among patients receiving long-term
kidney replacement therapy (KRT). However, it is not known whether primary kidney dis-
ease modifies the effect of comorbidities on KRT patients’ survival.
Methods
An incident cohort of all patients (n = 8696) entering chronic KRT in Finland in 2000–2017
was followed until death or end of 2017. All data were obtained from the Finnish Registry
for Kidney Diseases. Information on comorbidities (coronary artery disease, peripheral
vascular disease, left ventricular hypertrophy, heart failure, cerebrovascular disease,
malignancy, obesity, underweight, and hypertension) was collected at the start of KRT.
The main outcome measure was relative risk of death according to comorbidities
analyzed in six groups of primary kidney disease: type 2 diabetes, type 1 diabetes,
glomerulonephritis (GN), polycystic kidney disease (PKD), nephrosclerosis, and other or
unknown diagnoses. Kaplan-Meier estimates and Cox regression were used for survival
analyses.
Results
In the multivariable model, heart failure increased the risk of death threefold among PKD
and GN patients, whereas in patients with other kidney diagnoses the increased risk was
less than twofold. Obesity was associated with worse survival only among GN patients.
Presence of three or more comorbidities increased the age- and sex-adjusted relative risk of
death 4.5-fold in GN and PKD patients, but the increase was only 2.5-fold in patients in other
diagnosis groups.
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Conclusions
Primary kidney disease should be considered when assessing the effect of comorbidities on
survival of KRT patients as it varies significantly according to type of primary kidney
disease.
Introduction
Many of the patients entering long-term kidney replacement therapy (KRT) have other medi-
cal conditions as well [1,2]. In addition, cause of kidney failure is associated with the frequency
of comorbidities; for instance, KRT patients with diabetic nephropathy have more comorbidi-
ties than patients with other causes of kidney disease [3,4].
Several studies have shown that the effect of both comorbidities and of primary kidney dis-
ease is significant on KRT patients’ survival [5,6]. However, Van Manen et al. [7] reported that
adding comorbidities to a multivariable model on top of primary kidney disease and general
patient characteristics had only a small impact on hazard ratios of death. Nevertheless, all pub-
lished models predicting risk of death for patients starting dialysis assume that the effect of
comorbidities on survival is constant despite primary kidney disease [8].
Knowledge on whether primary kidney disease modifies the effect of comorbidities on sur-
vival is scarce or nonexistent. This study shows how comorbidities are associated with mortal-
ity according to primary kidney disease.
Materials and methods
All data were obtained from the Finnish Registry for Kidney Diseases. This registry has 97–
99% coverage of all Finnish patients on chronic KRT since 1965. The registry is maintained by
the Finnish Liver and Kidney Association and financed by the Finnish government. All
patients aged 18 years or older who entered chronic KRT in an outpatient setting from 1 Janu-
ary 2000 to 31 December 2017 were included in the study (n = 8696). Information on age at
start of KRT, sex, cause of kidney disease coded using ICD-10 codes, type of KRT (hemodialy-
sis, peritoneal dialysis, or kidney transplantation), and time and cause of death were collected.
Data on comorbidities (coronary artery disease, peripheral vascular disease, left ventricular
hypertrophy, heart failure, cerebrovascular disease, and malignancy) had been collected at
start of KRT as well as data on blood pressure and body mass index (BMI). The cut-off value
for obesity was set at BMI>30 kg/m2 and for underweight at BMI<20 kg/m2.
The patients were followed from the start of KRT until death (55.1%), loss to follow-up
(0.1%), moving abroad (0.2%), recovery of kidney function (1.9%), or end of follow-up on 31
December 2017 (42.7%). We divided the patients into six groups according to their primary
kidney disease: type 2 diabetes, type 1 diabetes, glomerulonephritis (GN), polycystic kidney
disease (PKD), nephrosclerosis, and other or unknown diagnoses. Information on comorbidi-
ties was available for 89% (left ventricular hypertrophy) to 97% (coronary artery disease) of
patients. Information on all comorbidities was available for 85% of patients. Multiple imputa-
tion was used for sensitivity analyses.
The Finnish Registry for Kidney Diseases collects written informed consent from all
patients for use of data for research purposes. The nephrological centers in Finland provide
data on all patients at start of chronic KRT and once a year thereafter to the Finnish Registry
for Kidney Diseases and these patient records are stored in the registry database. This study
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was approved by the Board of the Finnish Registry for Kidney Diseases and conducted in
accordance with the Data Protection Law. The patient records used here were pseudonymized,
the data were encrypted, and only specified persons of the research group had access to the
database. Thus, individuals cannot be identified from the results, and the study was based
entirely on previously collected registry data. The dataset for this study was retrieved from the
database of the Finnish Registry for Kidney Diseases in November 2018.
Statistical methods
Between-group comparisons were performed using χ2 test for categorical variables and the
Kruskal-Wallis test for continuous variables. Survival probabilities were calculated using
Kaplan-Meier curves, and differences between groups were assessed using the log-rank test.
Relative risks of death as a function of comorbidity were estimated using Cox proportional
hazards regression with and without adjustment for potential confounding factors. Death was
the event and patients were censored at the last day of follow-up or at the latest on 31 Decem-
ber 2017. Patients were not censored at kidney transplantation in the main analyses. Interac-
tions between diagnosis group and comorbidities were assessed by including interaction terms
in Cox regression with and without adjustment to determine whether the effect of comorbidity
on survival differs according to diagnosis group. Two-sided p values lower than 0.05 were con-
sidered significant.
Statistical analyses were performed using SPSS Statistics, version 25.0.
Results
Baseline characteristics
Of the 8696 patients (41 793 patient-years), 4793 died during follow-up. Table 1 presents base-
line characteristics, follow-up, and survival by diagnosis group. Median age at start of KRT
was the lowest, 47.3 years, among patients with type 1 diabetes and the highest, 72.7 years,
among patients with nephrosclerosis. Median survival time of all patients was 5.4 years,













All patients P value
Number of patients (%) 1720 (19.8) 1315 (15.1) 1207 (13.9) 826 (9.5) 539 (6.2) 3089 (35.5) 8696 (100)
Kidney biopsy, % 13.5 7.6 86.7 1.8 27.9 29.1 28.3 <0.001
Male gender, % 69.0 65.5 71.6 51.7 72.7 62.8 65.2 <0.001






59.7 (46.8–69.2) 57.9 (51.1–64.8) 71.8 (62.5–
78.5)
67.5 (56.3–75.8) 63.2 (51.6–
72.2)
<0.001






5.00 (1.97–9.56) 5.97 (2.78–10.58) 2.67 (1.21–
5.16)
2.95 (1.12–6.20) 3.41 (1.41–
7.02)
<0.001
Hemodialysis as the first treatment
modality, %
83.1 55.6 68.2 77.7 76.1 81.1 75.2 <0.001
Kidney transplantation during follow-
up, N (N/100 patient-years)
186 (3.1) 628 (8.7) 609 (8.1) 557 (9.6) 105 (5.1) 739 (5.6) 2824 (6.8) <0.001






15.41 (N/A) 4.02 (3.53–
4.51)
4.45 (4.19–4.72) 5.39 (5.18–
5.60)
<0.001
Number of deaths (N/100 patient-
years)
1294 (21.6) 619 (8.6) 445 (5.9) 236 (4.1) 342 (16.7) 1857 (14.0) 4793 (11.5) <0.001
Cardiovascular cause of death, % 46.8 57.0 44.0 37.7 45.3 31.8 41.5 <0.001
95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0256522.t001
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ranging from 3.3 years in patients with type 2 diabetes to 15.4 years in patients with PKD. The
most common cause of death was cardiovascular disease, accounting for 42% of the deceased
patients. Hemodialysis was the initial treatment modality in 75% and peritoneal dialysis in
25% of patients. Of all patients, 2% started in home hemodialysis and 33% received a kidney
transplant during follow-up.
More than half of the patients had at least one comorbidity (coronary artery disease, periph-
eral vascular disease, left ventricular hypertrophy, heart failure, cerebrovascular disease, or
malignancy). Left ventricular hypertrophy (in 33%) and coronary artery disease (in 25%) were
the most common comorbidities. Patients with type 2 diabetes or nephrosclerosis as the cause
of kidney failure had significantly more comorbidities than other patients, and the number of
comorbidities was the lowest in patients with PKD. Obesity was more common in those with
type 2 diabetes than in other groups. Systolic blood pressure was elevated in two-thirds and
diastolic blood pressure in one-quarter of patients despite the high prevalence of medication
for hypertension (Table 2).
Comorbidities and relative risk of death
Without adjustment, all comorbidities, obesity, and underweight were associated with
increased risk of death, and only elevated blood pressure was associated with decreased risk
of death regardless of whether patients were on medication for high blood pressure. The rel-
ative risk of death that was associated with each comorbidity varied significantly according
to primary kidney disease. Relative risk of death associated with presence of heart failure
varied the most, from 1.91 (95% CI 1.66–2.19) in patients with type 2 diabetes to 6.61 (95%
















Coronary artery disease 41.2 24.5 14.1 10.7 39.2 22.3 25.2 <0.001
Peripheral vascular disease 28.8 20.2 4.7 4.2 25.2 10.2 15.0 <0.001
Left ventricular hypertrophy 48.3 33.2 26.4 21.9 51.3 27.2 33.0 <0.001
Cerebrovascular disease 16.9 11.9 9.0 9.6 15.5 8.6 11.3 <0.001
Heart failure 19.5 7.3 5.2 2.1 14.2 10.7 10.5 <0.001
Malignancy 9.9 3.5 8.0 6.5 14.3 19.8 12.1 <0.001
One comorbiditya 30.1 29.4 27.4 27.4 33.3 32.2 30.3 <0.001
Two comorbiditiesa 24.2 15.4 10.6 8.9 21.7 14.9 16.1 <0.001
Three or more
comorbiditiesa
22.6 10.8 4.9 2.7 22.4 10.0 12.0 <0.001
Obesity (BMI > 30 kg/m2) 47.5 16.4 23.1 17.4 19.1 16.7 23.9 <0.001
Underweight (BMI < 20 kg/
m2)
1.8 6.5 6.4 4.2 4.8 8.6 6.0 <0.001
Systolic blood
pressure > 140 mmHg
72.4 76.7 68.3 62.6 69.7 56.4 65.7 <0.001
Diastolic blood
pressure > 90 mmHg
15.5 31.0 35.5 31.2 22.6 20.2 24.3 <0.001
Medication for hypertension 95.0 96.6 94.0 92.5 95.6 78.2 88.9 <0.001
Medication for dyslipidemia 73.7 71.5 55.2 45.4 58.4 38.0 54.6 <0.001
BMI, body mass index.
aOf the six comorbidities above.
https://doi.org/10.1371/journal.pone.0256522.t002
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CI 3.57–12.22) in patients with PKD, when the risk of death was compared with patients
who did not have heart failure within the same diagnosis group (S1 Table).
When adjusted for age and sex, primary kidney disease significantly modified the effect of
coronary artery disease, heart failure, and malignancy on death, as all of these increased risk of
death more in PKD and GN patients than in other patients (S2 Table). Obesity was associated
with increased risk of death only in patients with GN. Underweight was also associated with
worse prognosis, especially among patients with type 1 diabetes or nephrosclerosis.
In the multivariable model (Table 3), coronary artery disease, heart failure, and higher age
had the strongest effect on worse prognosis in patients with GN or PKD. Malignancy had the
most marked worsening effect on prognosis in patients with PKD. Similar to the less adjusted
model, in our multivariable model the risk of death that was associated with underweight was
the highest in patients with type 1 diabetes, and obesity was associated with worse prognosis
only in GN patients.
Patients for whom we had all comorbidity data had better survival than patients with non-
complete comorbidity data, and median survival times were 5.57 (95% CI 5.32–5.82) years and
4.63 (95% CI 4.25–5.01) years, respectively. Multiple imputation of missing comorbidity data
did not change our results. When patients were censored at time of kidney transplantation, the
Table 3. Multivariable model of comorbidities’ effect on relative risk of death according to primary kidney disease.












All patients Interaction P
valuea




1.58 (1.21–2.07) 1.79 (1.21–2.66) 1.09 (0.81–
1.46)
1.19 (1.04–1.36) 1.29 (1.19–
1.40)
<0.001




1.24 (0.81–1.89) 1.64 (0.97–2.77) 1.47 (1.09–
1.97)









1.17 (0.92–1.48) 1.11 (0.79–1.56) 1.14 (0.86–
1.50)
1.11 (0.99–1.26) 1.13 (1.05–
1.22)
0.070




1.52 (1.08–2.14) 1.08 (0.68–1.72) 1.34 (0.93–
1.92)
1.26 (1.07–1.50) 1.24 (1.12–
1.36)
0.581




3.18 (2.10–4.83) 3.05 (1.46–6.36) 1.87 (1.28–
2.72)







1.34 (0.97–1.86) 1.92 (1.18–3.11) 0.72 (0.51–
1.03)
1.20 (1.06–1.36) 1.18 (1.07–
1.29)
<0.001
Normal weight (BMI 20–
30 kg/m2)
1 1 1 1 1 1 1 0.002




2.04 (1.59–2.61) 0.87 (0.59–1.29) 0.85 (0.61–
1.20)
0.98 (0.85–1.13) 1.14 (1.05–
1.22)






1.43 (0.93–2.21) 1.45 (0.77–2.73) 1.35 (0.74–
2.46)
1.54 (1.30–1.83) 1.53 (1.35–
1.74)
Systolic blood





0.96 (0.76–1.23) 1.07 (0.78–2.73) 1.11 (0.82–
1.50)









0.89 (0.67–1.18) 0.85 (0.60–1.20) 0.77 (0.55–
1.08)
1.03 (0.89–1.20) 0.88 (0.80–
0.96)
0.060






2.29 (2.04–2.58) 2.11 (1.78–2.51) 1.87 (1.61–
2.17)
1.63 (1.56–1.72) 1.62 (1.57–
1.67)
<0.001




1.02 (0.79–1.31) 0.85 (0.63–1.15) 0.85 (0.63–
1.14)
1.08 (0.97–1.21) 1.00 (0.93–
1.07)
0.593
aInteraction between diagnosis group and comorbidity.
RR, relative risk of death; 95% CI, 95% confidence interval; BMI, body mass index.
Separate multivariable models were made for each diagnosis group (in columns) including all comorbidities in the table.
https://doi.org/10.1371/journal.pone.0256522.t003
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differences in comorbidities’ association with risk of death according to primary kidney dis-
ease remained similar to results without censoring at kidney transplantation.
Number of comorbidities and risk of death
Six comorbidities (coronary artery disease, peripheral vascular disease, left ventricular hyper-
trophy, heart failure, cerebrovascular disease, and malignancy) were included in the survival
analyses on number of comorbidities. Increasing number of comorbidities was associated with
higher risk of death in all primary kidney disease groups, but after adjustment for age and sex,
the increase was more significant among patients with GN or PKD. Three or more comorbidi-
ties, compared with no comorbidity, increased risk of death 4.62-fold in patients with GN and
4.36-fold in patients with PKD, whereas relative risk varied from 2.25 to 2.63 in other primary
kidney disease groups (S3 Table). Furthermore, survival time varied markedly in primary kid-
ney disease groups according to number of comorbidities. In patients without comorbidities,
median survival ranged from 4.9 years (patients with type 2 diabetes) to more than 18 years
(PKD patients). However, if patients had three or more comorbidities the variation in median
survival time was much smaller: from 1.5 years in GN patients to 2.9 years in PKD patients
(Fig 1). This also indicates that the number of comorbidities is more relevant to the survival
prognosis in patients with PKD and GN than in other diagnostic groups.
Discussion
Our study shows that comorbidities affect KRT patients’ risk of death differently depending on
the type of primary kidney disease. This study included all adult patients who entered long-
term KRT during 2000–2017 in Finland. A significantly greater increase in risk of death was
seen in PKD and GN patients with heart failure, coronary artery disease, or malignancy than
with other diagnoses, when comparing patients in the same diagnosis group with or without
these comorbidities. PKD or GN patients diagnosed with heart failure before start of KRT
showed a fivefold age- and sex-adjusted risk of death relative to those without this comorbid-
ity, whereas among patients with other primary kidney diseases the increase was only twofold.
PKD and GN patients had less comorbidities and better survival than other KRT patients.
However, if these patients had multiple comorbidities their survival was similar to other
patients with multiple comorbidities due to the greater effect of comorbidities in the survival
prognosis in patients with PKD or GN than in patients with other diagnoses. To our knowl-
edge, no previously published study has assessed this primary kidney disease-related variation
in comorbidities’ effect on mortality.
This nationwide study included all patients starting KRT in Finland during the 18-years
study period. Data on mortality were complete, the number of patients lost to follow-up was
very low, data were collected in a similar manner throughout the study period, and data on the
most important comorbidities were available for a large proportion of patients. Therefore, the
possibility of selection or information bias was minimal. However, a few limitations should be
noted. The population in Finland is genetically quite homogeneous and almost entirely white,
which may reduce the generalizability of the findings. Another potential limitation is that
comorbidity data were collected mainly from pre-existing information, that is, patients were
not examined separately for registry purposes. This could cause reporting bias since more
severe cases were more likely reported. We also had no information on severity of comorbidi-
ties. Results of a study from the Netherlands, however, showed that adding severity grading of
several comorbid conditions did not lead to improved prognostic power [9]. Although we did
not have complete information on comorbidities, the data we used were significantly more
comprehensive in this respect than the data used in some previous registry studies [5,10,11].
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Generally, when comparing the results of our study with results of earlier ones from other
countries, it is crucial that diagnoses of primary kidney disease groups and classification of
comorbid conditions are comparable. Diabetes is the leading cause of end-stage kidney disease
(ESKD) in most of the countries, but incidence of ESKD caused by type 1 diabetes is higher in
Finland than in other countries. The ERA-EDTA Registry, the United States Renal Data Sys-
tem, and previous studies have reported higher proportions of incident KRT patients with
hypertension or renal vascular disease as the cause of kidney disease than we report here
[5,7,12,13]. Some of the differences may emerge from differences between populations, but
also classification of primary kidney disease may differ. Definitions of comorbidities and
methods of data collection are likely to have an impact on reported numbers of comorbidities.
Previous studies have described a higher incidence of peripheral vascular disease and heart
failure at the start of KRT, whereas incidence of coronary artery disease, cerebrovascular dis-
ease, and malignancies has been similar to our study [2,4,5,7,14].
Fig 1. Effect of the number of comorbidities on unadjusted survival probability according to primary kidney
disease.
https://doi.org/10.1371/journal.pone.0256522.g001
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All six major comorbidities reported here have also earlier been shown to be associated
with increased mortality [2,6,14–16]. Of note, van Manen et al. [7] showed that the influence
of comorbidities may be less important than expected, explaining only 1.9% of the variance in
mortality. Underweight has previously been established to be associated with an increased risk
of death, but the association between obesity and mortality among GN patients shown here,
has not been published earlier [17–20]. Although treatment of hypertension reduces mortality
among patients on hemodialysis [21], hypertension has been demonstrated to have an inverse
association with mortality in epidemiological studies [6,22], which is in line with our results.
This may be due to an increased risk of death associated with intradialytic hypotension [23].
Taken together, our results on the entire KRT population resemble those of previous studies,
and this supports the generalizability of our findings on how primary kidney disease modifies
the effect of comorbidities on survival.
How could the results of our study be interpreted? Lower age in GN and PKD patients
could be one explanation. If malignancy is diagnosed at a younger age, it is more likely to be
more aggressive than among older patients, thus worsening the prognosis more in a young
population. In addition, conservative treatment for ESKD may have been chosen more often
for elderly patients who have malignancy with a poor prognosis. However, although patients
with type 1 diabetes in our study were younger than GN and PKD patients, their risk of death
associated with malignancy was lower. Lower risk of malignancy-related mortality in patients
with diabetes than in patients with GN has been reported previously and may be caused by a
higher risk of cardiovascular death in patients with diabetes as a competing factor [24]. Cardio-
vascular morbidity is high in patients with diabetes and in elderly patients and some of these
patients may have undiagnosed coronary artery disease and heart failure. Consequently, had
some of these patients been misclassified as not having these comorbidities, this would have
diluted the association with comorbidity and mortality and could explain the stronger associa-
tion with mortality in GN and PKD patients. In addition, higher overall risk of death in
patients with diabetes and in elderly patients may reduce the additional effect of comorbidities
on mortality. Furthermore, severity and type of comorbid disease at time of diagnosis and the
different treatments for these comorbidities may have influenced our results.
In conclusion, comorbidities affect KRT patients’ survival differently depending on the type
of primary kidney disease. When assessing prognosis of patients with GN or PKD, especially
cardiological problems and malignancies should be taken into account. Our findings should
be considered when building prognostic models that include comorbidities, because otherwise
these models are not accurate, and the estimates calculated with these models may lead to
wrong conclusions for some patients. Future studies could shed more light on potential differ-
ences in severity or nature of comorbidities according to primary kidney disease. To avoid
known shortcomings of an observational study like ours, a randomized study could reveal
whether systematic screening and treatment of comorbidities in patients starting KRT would
improve their survival.
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